Holen Sie sich die Stockscreener-App
6.35
0.95%
0.06
Handel nachbörslich:
6.24
-0.11
-1.73%
Schlusskurs vom Vortag:
$6.29
Offen:
$6.32
24-Stunden-Volumen:
3.05M
Relative Volume:
4.50
Marktkapitalisierung:
$435.83M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-96.66M
KGV:
-2.9535
EPS:
-2.15
Netto-Cashflow:
$-83.73M
1W Leistung:
+15.04%
1M Leistung:
+17.38%
6M Leistung:
+51.19%
1J Leistung:
-44.54%
1-Tages-Spanne:
$5.985
$6.40
1-Wochen-Bereich:
$5.36
$6.85
52-Wochen-Spanne:
$2.86
$13.93
Olema Pharmaceuticals Inc Stock (OLMA) Company Profile
Firmenname
Olema Pharmaceuticals Inc
Sektor
Branche
Telefon
(415) 651-3316
Adresse
780 BRANNAN STREET, SAN FRANCISCO
Vergleichen Sie OLMA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
OLMA
Olema Pharmaceuticals Inc
|
6.35 | 444.06M | 0 | -96.66M | -83.73M | -2.15 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.93 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.54 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.22 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
733.66 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
318.73 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Olema Pharmaceuticals Inc Stock (OLMA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-12 | Bestätigt | Citigroup | Buy |
| 2024-04-02 | Eingeleitet | Goldman | Buy |
| 2024-01-30 | Eingeleitet | Citigroup | Buy |
| 2023-07-21 | Eingeleitet | Oppenheimer | Outperform |
| 2023-05-05 | Eingeleitet | CapitalOne | Overweight |
| 2023-02-22 | Eingeleitet | Credit Suisse | Outperform |
| 2022-07-06 | Fortgesetzt | Canaccord Genuity | Buy |
| 2022-06-09 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2022-02-28 | Eingeleitet | H.C. Wainwright | Neutral |
| 2021-12-07 | Fortgesetzt | Cowen | Outperform |
| 2020-12-14 | Eingeleitet | Canaccord Genuity | Buy |
| 2020-12-14 | Eingeleitet | Cowen | Outperform |
| 2020-12-14 | Eingeleitet | JP Morgan | Overweight |
| 2020-12-14 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Olema Pharmaceuticals Inc Aktie (OLMA) Neueste Nachrichten
Olema Oncology’s Strategic Use of Equity Incentives to Fuel R&D and Talent Growth - AInvest
Olema Pharmaceuticals Grants Stock Options to New Employees Under 2022 Inducement Plan - Quiver Quantitative
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
124,000 Shares: Olema Oncology Grants New Employee Stock Options with 4-Year Vesting Terms - Stock Titan
Pfizer collaboration with Olema may spark future bidding waranalyst - MSN
Wellington Management Group LLP Lowers Holdings in Olema Pharmaceuticals, Inc. $OLMA - MarketBeat
Pfizer's partnership with Olema may spark a bidding war for the biotech firm. - AInvest
Pfizer (PFE) Partners With Olema For New Metastatic Breast Cancer Study - simplywall.st
Is Olema Pharmaceuticals Inc. likely to announce a buybackJuly 2025 Intraday Action & Weekly Sector Rotation Insights - khodrobank.com
Signal strength of Olema Pharmaceuticals Inc. stock in tech scannersJuly 2025 Snapshot & Advanced Swing Trade Entry Plans - Newser
When is the best time to exit Olema Pharmaceuticals Inc.Gap Down & High Conviction Buy Zone Picks - Newser
H.C. Wainwright reiterates Buy rating on Olema Pharmaceuticals stock - Investing.com
What MACD and RSI say about Olema Pharmaceuticals Inc.Market Risk Report & Weekly High Return Stock Opportunities - Newser
How to read the order book for Olema Pharmaceuticals Inc.2025 Market Sentiment & Expert Verified Movement Alerts - Newser
How does Olema Pharmaceuticals Inc. correlate with NasdaqTrade Volume Summary & Safe Capital Allocation Plans - khodrobank.com
Olema Pharmaceuticals Inc. recovery potential after sell offWeekly Market Report & Risk Controlled Daily Trade Plans - Newser
Olema Pharmaceuticals Inc. stock trendline breakdownJuly 2025 Volume & Consistent Profit Trading Strategies - Newser
What technical models suggest about Olema Pharmaceuticals Inc.’s comeback2025 Top Gainers & Verified Short-Term Trading Plans - Newser
Olema Pharmaceuticals Inc. stock outlook for YEARWeekly Trend Report & Risk Controlled Daily Trade Plans - Newser
Why Olema Pharmaceuticals Inc. is moving today2025 Short Interest & Growth Focused Entry Point Reports - Newser
Is Olema Pharmaceuticals Inc. stock poised for growthEarnings Beat & Weekly Watchlist of Top Performers - Newser
What data driven models say about Olema Pharmaceuticals Inc.’s futureTrade Risk Summary & Weekly High Return Stock Opportunities - Newser
Real time scanner hits for Olema Pharmaceuticals Inc. explainedInflation Watch & Technical Pattern Based Buy Signals - Newser
Does Olema Pharmaceuticals Inc. outperform in volatile markets2025 Key Lessons & Real-Time Stock Price Movement Reports - khodrobank.com
Published on: 2025-09-03 00:18:58 - Newser
How high can Olema Pharmaceuticals Inc. stock goDollar Strength & Fast Gain Stock Trading Tips - Newser
Is Olema Pharmaceuticals Inc. a strong candidate for buy and holdJuly 2025 Setups & Daily Profit Focused Stock Screening - khodrobank.com
Regression analysis insights on Olema Pharmaceuticals Inc. performanceFed Meeting & Accurate Entry/Exit Alerts - Newser
Using portfolio simulators with Olema Pharmaceuticals Inc. includedWall Street Watch & Expert Curated Trade Ideas - Newser
Will Olema Pharmaceuticals Inc. stock recover after earningsMarket Growth Summary & Weekly Watchlist of Top Performers - khodrobank.com
Olema Pharmaceuticals Partners with Pfizer for New Trial - MSN
Olema stock jumps after new clinical trial collaboration with Pfizer - Investing.com
Multi factor analysis applied to Olema Pharmaceuticals Inc.2025 Market Outlook & Proven Capital Preservation Tips - Newser
Olema Pharmaceuticals shares rise 2.93% premarket after announcing a new clinical trial collaboration with Pfizer. - AInvest
Olema Pharmaceuticals, Pfizer Collaborate for Clinical Trial of Breast Cancer Treatment - MarketScreener
Paradigm Biocapital Advisors LP Has $25.35 Million Holdings in Olema Pharmaceuticals, Inc. $OLMA - MarketBeat
Olema Oncology Announces New Clinical Trial Agreement with - GlobeNewswire
Is Olema Pharmaceuticals Inc. a top pick in the sectorDay Trade & Free Growth Oriented Trading Recommendations - khodrobank.com
Novel Breast Cancer Treatment: Olema and Pfizer Join Forces on Promising Drug Combination Study - Stock Titan
Is Olema Pharmaceuticals Inc. trending in predictive chart modelsGap Up & Risk Adjusted Swing Trade Ideas - Newser
Is Olema Pharmaceuticals Inc. a defensive stockJuly 2025 PostEarnings & Accurate Intraday Trade Tips - khodrobank.com
Combining price and volume data for Olema Pharmaceuticals Inc.2025 Price Targets & Long-Term Investment Growth Plans - Newser
Affinity Asset Advisors LLC Invests $1.22 Million in Olema Pharmaceuticals, Inc. $OLMA - MarketBeat
Is it too late to sell Olema Pharmaceuticals Inc.July 2025 Big Picture & Smart Swing Trading Alerts - Newser
Finanzdaten der Olema Pharmaceuticals Inc-Aktie (OLMA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Olema Pharmaceuticals Inc-Aktie (OLMA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Graham G. Walmsley | Director |
Dec 17 '24 |
Sale |
6.75 |
700,761 |
4,730,137 |
0 |
| Zojwalla Naseem | CHIEF MEDICAL OFFICER |
Dec 16 '24 |
Option Exercise |
4.87 |
14,000 |
68,180 |
129,509 |
1.75%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):